A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors

Blood

Volumn 94, Issue 8, 1999, Pages 2562-2568

  Arndt, Michaela A E ^b   Krauss, Jürgen ^b   Kipriyanov, Sergey M ^b   Pfreundschuh, Michael ^b   Little, Melvyn ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD30 ANTIGEN; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TARGET CELL; XENOTRANSPLANTATION;

EID: 0032855541     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.8.2562.420k20_2562_2568     Document Type: Article

References (32)

1. Herberman RB, Ortaldo JR: Natural killer cells: The role in defense against disease. Science 214:24, 1981
2. Gudelj L, Deniz G, Rukavina D, Johnson PM, Christmas SE: Expression of functional molecules by human CD3-decidual granular leucocyte clones. Immunology 87:609, 1996
3. + human natural killer cells. Int J Cancer 44:727, 1989
4. Fanger MW, Morganelli PM, Guyre PM: Use of bispecific antibodies in the therapy of tumors. Cancer Treat Res 68:181, 1993
5. Hombach A, Jung W, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M: A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830, 1993
6. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter B, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
7. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042, 1997
8. Gruber M, Schodin BA, Wilson ER, Kranz DM: Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 152:5368, 1994
9. Mack M, Riethmüller G, Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92:7021, 1995
10. Holliger P, Prospero T, Winter G: "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444, 1993
11. Holliger P, Brissinck J, Williams RL, Thielmans K, Winter G: Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9:299, 1996
12. Atwell JL, Pearce LA, Lah M, Gruen LC, Kortt A, Hudson P: Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neurominidase. Mol Immunol 33:1301, 1996
13. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P: High-Level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14:192, 1996
14. Perisic O, Webb PA, Holliger P, Winter G, Williams RL: Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217, 1994
15. Kipriyanov SM, Kupriyanova OA, Little M, Moldenhauer G: Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. J Immunol Methods 196:51, 1996
16. Kipriyanov SM, Moldenhauer G, Srauss G, Little M: Bispecific CD3 X CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 77:763, 1998
17. Hombach A, Pohl C, Heuser C, Sircar R, Diehl V, Abken H: Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies. J Immunol Methods 218:53, 1998
18. Pfreundschuh M, Mommertz E, Meissner M, Feller AC, Hassa R, Krueger GRF, Diehl V: Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Res 8:217, 1988
19. Engert A, Martin G, Preundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P: Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab′ fragments on solid human Hodgkin's disease tumors in mice. Cancer Res 50:2929, 1990
20. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A, Kapp U, Fonatsch C, Komitowski D, Féaux de Lacroix W, Diehl V: Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer 52:887, 1992
21. Sanger F, Nicklen S, Coulson R: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463, 1977
22. Kipriyanov SM, Moldenhauer G, Martin ACR, Kupriyanova OA, Little M: Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 10:445, 1997
23. Kipriyanov SM, Moldenhauer G, Little M: High level production of soluble single chain antibodies in small-scale Eschericha coli cultures. J Immunol Methods 200:69, 1997
24. Matzinger P: The JAM test. J Immunol Methods 145:185, 1991
25. Renner C, Pfreundschuh M: Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. J Hematother 4:447, 1995
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
27. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719, 1959
28. Horn U, Strittmatter W, Krebber A, Knupfer U, Kujau M, Wenderoth R, Müller K, Matzku S, Plückthun A, Riesenberg D: High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol 46:524, 1996
29. Huston JS, George AJT, Adams GP, Stafford WF, Jamar F, Tai MS, McCartney JE, Oppermann H, Heelan BT, Peters AM, Houston LL, Bookman MA, Wolf EJ, Weiner LM: Single-chain Fv radioimmunotargeting. Q J Nucl Med 40:320, 1996
30. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD: Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77:1405, 1998
31. Weiner LM, Houston LL, Huston JS, McCartney JE, Tai MS, Apell G, Stafford WF, Bookman MA, Gallo JM, Adams GP: Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting 1:51, 1995
32. Yokota T, Milenic DE, Withlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunglobulin forms. Cancer Res 52:3402, 1992